PSMA has emerged as a promising protein target for prostate cancer for both diagnosis and therapeutic purposes (e.g., radionuclide-based therapy or other therapeutic strategies including immunotoxins, immune cells retargeting, prodrug activation, PSMA vaccines, plasmid DNA, and adenoviral immunizations.30-32 This mechanism leads to the internalization of radionuclides into the cancer cells and eventually causes cell death33 as shown in Figure 2. This evidence concerns the gene FOLH1 and Familial prostate cancer.